Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962904 · ClinicalTrials.gov registry record · Phase 1
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
A Phase 1 study of Rotavirus Infections, sponsored by Centers for Disease Control and Prevention.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06962904: Active Phase 1 study of Rotavirus Infections, sponsored by Centers for Disease Control and Prevention.
NCT06962904 is a Phase 1 study of Rotavirus Infections that is active but no longer recruiting, run by Centers for Disease Control and Prevention. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06962904, a Phase 1 study of Rotavirus Infections, is active but no longer recruiting, sponsored by Centers for Disease Control and Prevention.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Primary Outcome
The number of vaccine-related unsolicited adverse events following each vaccination. Unsolicited AEs will be collected continuously from vaccination on Day 1 through 28 days after the last vaccination (Day 85)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
- BIOLOGICAL 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
Study Locations (1)
Georgia
- Emory Children's Center - Vaccine Research Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2026-10-06 |
| Phase | Phase 1 |
What the registry record for NCT06962904 still lists
NCT06962904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Rotavirus Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06962904 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06962904 about?
NCT06962904 is a clinical study titled "CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults". This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
What is the current status of trial NCT06962904?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-07-07. Estimated completion is 2026-10-06.
What conditions does trial NCT06962904 study?
This clinical trial studies the following conditions: Rotavirus Infections.
What interventions are being tested in trial NCT06962904?
The interventions under investigation include: Placebo (OTHER), 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV) (BIOLOGICAL), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06962904?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06962904 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06962904's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI